Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
Phase 4
Terminated
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Registration Number
- NCT00471068
- Lead Sponsor
- Alcon Research
- Brief Summary
To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
- Patient with open-angle glaucoma or ocular hypertension
Exclusion Criteria
- By Age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Travatan Travatan Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s) Travatan Placebo (Timolol Vehicle) Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s) Cosopt Cosopt treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
- Primary Outcome Measures
Name Time Method Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment At week 0 and week 6 IOP measured at week 6 minus IOP measured at baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Coimbra
🇵🇹Coimbra, Portugal